1577-31-7 Usage
General Description
(Z)-2-Heptenoic acid is a chemical compound with a molecular formula C7H12O2. It is a colorless liquid with a characteristic fruity odor and is commonly used in the fragrance industry as a flavoring agent in food and beverages. It is also used in the production of synthetic perfumes and as a precursor for the synthesis of other chemical compounds. (Z)-2-Heptenoic acid is known for its antimicrobial properties and is used in the formulation of antimicrobial agents. Additionally, it has potential applications in the pharmaceutical industry for its biological and pharmacological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 1577-31-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,7 and 7 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1577-31:
(6*1)+(5*5)+(4*7)+(3*7)+(2*3)+(1*1)=87
87 % 10 = 7
So 1577-31-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H12O2/c1-2-3-4-5-6-7(8)9/h5-6H,2-4H2,1H3,(H,8,9)/b6-5-
1577-31-7Relevant articles and documents
Alexakis et al.
, p. 3461 (1976)
Carbamoyl substituted heterocycles
-
, (2008/06/13)
This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.
Carbamoyl substituted oxazoles as thromboxane receptor antagonists
-
, (2008/06/13)
This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.